The primary mission of Mary Crowley is to advance promising therapies toward FDA approval so that all cancer patients may benefit from them. This September, the Food and Drug Administration granted accelerated approval to futibatinib, a genomic therapy first available to our patients at Mary Crowley via clinical trial. Because of the insight and experience of our highly respected clinical staff, Mary Crowley can identify the most promising therapies and bring them to North Texas for waiting patients. We are grateful for the courage and persistence of our patients who, by participating in clinical trials, move science forward for cancer patients in the future.
I am also excited to announce that we are planning to open additional Mary Crowley trial clinics in 2023. This expansion will allow us to serve more patients than ever before and provide access to even more cutting-edge clinical trials all over North Texas. All the while, we will maintain the integrity and personal touch with our patients that we are known for.
Finally, Mary Crowley won the D CEO Nonprofit Award this year for Innovation in Healthcare. We are thrilled to be recognized in a category of well-known and well-respected healthcare nonprofits and grateful for the acknowledgment of Mary Crowley’s important and vital work in the cancer community.
Your generous support makes a difference in cancer patients’ lives every day. The trials you bring to our clinic give hope to cancer patients who face a grim diagnosis. Because of you, tangible results come to fruition, as Mary Crowley has now played a part in the FDA approval of 19 therapies now available to the general public. The need for more effective, less toxic treatments remains as urgent as ever. Please consider a tax-deductible donation today to bring light to cancer patients this holiday season. Thank you for your support.
Sincerely,
